PAXLOVID 6 Dosage Forms, Strengths, Composition And Packaging

Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

For Canadian
Healthcare ProfessionalsFor Canadian
Healthcare Professionals
SelectFor Canadian
Healthcare ProfessionalsFor Canadian
Healthcare Professionals
For Canadian
Patients, Consumers or CaregiversNo, go back to the patient portal
SelectFor Canadian
Patients, Consumers or CaregiversNo, go back to the patient portal
Site is intended for Canadian residents. For Non-Canada residents click here.

Table 2 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration

Dosage Form / Strength/Composition

Non-medicinal Ingredients

Oral

(co-packaged for use)

Nirmatrelvir

Tablet (pink): 150mg

 

Tablet core: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and sodium stearyl fumarate

Film coat: hydroxy propyl methylcellulose, iron oxide red, polyethylene glycol and titanium dioxide

Ritonavir

Tablet (white): 100mg

Tablet core: anhydrous dibasic calcium phosphate, colloidal silicon dioxide, copovidone, sodium stearyl fumarate, and sorbitan monolaurate.

Film coat: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, polyethylene glycol 400, polyethylene glycol 3350, polysorbate 80, talc and titanium dioxide.

PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. It is supplied in two different Dose Packs.

Nirmatrelvir tablets and ritonavir tablets are supplied in separate cavities within the same child resistant blister card.

Dose Packs

Content

Description

300 mg nirmatrelvir; 100 mg ritonavir

Each Carton Contains:
30 tablets divided in 5 daily-dose blister cards

Nirmatrelvir tablets: Oval, pink immediate-release, film‑coated tablets debossed with "PFE" on one side and "3CL" on the other side.

Ritonavir tablets: White film-coated ovaloid tablets debossed with the “a” logo and the code NK.

Each Blister Carda Contains:
4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each)

Nirmatrelvir tablets: Oval, pink immediate-release, film‑coated tablets debossed with "PFE" on one side and "3CL" on the other side.

Ritonavir tablets: White film-coated ovaloid tablets debossed with the “a” logo and the code NK.

150 mg nirmatrelvir; 100 mg ritonavir

Each Carton Contains:
20 tablets divided in 5 daily-dose blister cards

Nirmatrelvir tablets: Oval, pink immediate-release, film‑coated tablets debossed with "PFE" on one side and "3CL" on the other side.

Ritonavir tablets: White film-coated ovaloid tablets debossed with the “a” logo and the code NK.

Each Blister Carda Contains:
2 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each)

Nirmatrelvir tablets: Oval, pink immediate-release, film‑coated tablets debossed with "PFE" on one side and "3CL" on the other side.

Ritonavir tablets: White film-coated ovaloid tablets debossed with the “a” logo and the code NK.
a.
Indicates which tablets need to be taken in the morning and evening.